Drugs / CB dualCAR-NK19/70
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05667155 | Dec 2022 → Jan 2025 | B-cell non-Hodgkin lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB dualCAR-NK19/70 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05667155 ↗ |
| Modality | Cell therapy | “cord blood-derived CAR-NK cells” NCT05667155 ↗ |
| Route | Intravenous | “All subjects were intravenously administrated with CB dualCAR-NK19/70” NCT05667155 ↗ |
| Target | CD19 | “targeting CD19/CD70” NCT05667155 ↗ |
| Target | CD70 | “targeting CD19/CD70” NCT05667155 ↗ |